Liu X - Search Results

1

Association of KDR mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.

Cui Y, Zhang P, Liang X, Xu J, Liu X, Wu Y, Zhang J, Wang W, Zhang F, Guo R. Cui Y, et al. Among authors: liu x. Am J Cancer Res. 2022 Apr 15;12(4):1766-1783. eCollection 2022. Am J Cancer Res. 2022. PMID: 35530271 Free PMC article.

2

A Novel Long Non-Coding RNA, SOX21-AS1, Indicates a Poor Prognosis and Promotes Lung Adenocarcinoma Proliferation.

Lu X, Huang C, He X, Liu X, Ji J, Zhang E, Wang W, Guo R. Lu X, et al. Among authors: liu x. Cell Physiol Biochem. 2017;42(5):1857-1869. doi: 10.1159/000479543. Epub 2017 Jul 27. Cell Physiol Biochem. 2017. PMID: 28873379 Free article.

3

EZH2-Mediated Epigenetic Suppression of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small-Cell Lung Cancer.

Lu X, He X, Su J, Wang J, Liu X, Xu K, De W, Zhang E, Guo R, Shi YE. Lu X, et al. Among authors: liu x. Mol Ther Nucleic Acids. 2018 Sep 7;12:309-318. doi: 10.1016/j.omtn.2018.05.016. Epub 2018 Jun 30. Mol Ther Nucleic Acids. 2018. PMID: 30195769 Free PMC article.

4

LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC.

Liu X, Lu X, Zhen F, Jin S, Yu T, Zhu Q, Wang W, Xu K, Yao J, Guo R. Liu X, et al. Mol Ther Nucleic Acids. 2019 Jun 7;16:155-161. doi: 10.1016/j.omtn.2019.02.010. Epub 2019 Feb 21. Mol Ther Nucleic Acids. 2019. PMID: 30889481 Free PMC article.

5

Ferroptosis in cancer therapy: a novel approach to reversing drug resistance.

Zhang C, Liu X, Jin S, Chen Y, Guo R. Zhang C, et al. Among authors: liu x. Mol Cancer. 2022 Feb 12;21(1):47. doi: 10.1186/s12943-022-01530-y. Mol Cancer. 2022. PMID: 35151318 Free PMC article. Review.

6

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Cui Y, Liu X, Wu Y, Liang X, Dai J, Zhang Z, Guo R. Cui Y, et al. Among authors: liu x. Front Oncol. 2022 Mar 10;12:798401. doi: 10.3389/fonc.2022.798401. eCollection 2022. Front Oncol. 2022. PMID: 35359393 Free PMC article.

7

Copy number amplification and SP1-activated lncRNA MELTF-AS1 regulates tumorigenesis by driving phase separation of YBX1 to activate ANXA8 in non-small cell lung cancer.

Lu X, Wang J, Wang W, Lu C, Qu T, He X, Liu X, Guo R, Zhang E. Lu X, et al. Among authors: liu x. Oncogene. 2022 Jun;41(23):3222-3238. doi: 10.1038/s41388-022-02292-z. Epub 2022 May 4. Oncogene. 2022. PMID: 35508543

8

Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.

Gao W, Wu L, Jin S, Li J, Liu X, Xu J, Zhang W, Gong Q, Sun C, Wang W, Wang Z, Shao YW, Yin JC, Shen L, Chen L, Wang Q, Guo R. Gao W, et al. Among authors: liu x. J Immunother Cancer. 2022 Nov;10(11):e005970. doi: 10.1136/jitc-2022-005970. J Immunother Cancer. 2022. PMID: 36450378 Free PMC article.

9

Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.

Dai J, Liu X, Li J, Qu T, Cui Y, Jin S, Zhang E, Guo R. Dai J, et al. Among authors: liu x. Thorac Cancer. 2023 Feb;14(6):535-543. doi: 10.1111/1759-7714.14783. Epub 2023 Jan 2. Thorac Cancer. 2023. PMID: 36594109 Free PMC article. Review.

10

Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer.

Zhang C, Lu X, Liu X, Xu J, Li J, Qu T, Dai J, Guo R. Zhang C, et al. Among authors: liu x. Oxid Med Cell Longev. 2023 Jan 31;2023:1367938. doi: 10.1155/2023/1367938. eCollection 2023. Oxid Med Cell Longev. 2023. PMID: 36760347 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135,148 results

Search Page

Filters